Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

468 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1) infected individuals that have viral loads across the dynamic range of the Aptima HIV-1 assay. The plasma samples will be tested in a method comparison study to support the approval of the Aptima HIV-1 assay on Gen-Probe's Panther testing system. The objective of the method comparison study is to evaluate the clinical utility of the Aptima HIV-1 assay by comparing the results to the FDA-licensed COBAS assay (Roche Molecular Systems, Inc., Branchburg, New Jersey) in plasma samples that have viral loads across the dynamic range of the Aptima HIV-1 assay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acute HIV Infection Observational Study

NCT00296660

HIV Infections

COMPLETED

Consent for Use of Stored Patient Specimens for Future Testing

NCT00031408

HIV Infections

ACTIVE_NOT_RECRUITING

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

NCT00686205

Healthy Donors HIV Positive

COMPLETED PHASE3

Analysis of the Reservoir in Individuals Controlling HIV Infection

NCT06016114

Hiv

NOT_YET_RECRUITING

Evaluating Immune Function Tests in People With HIV

NCT00067795

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Population

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject has documented HIV infection
* The subject is at least 15 years of age at the time of enrollment
* For ART subjects, subject has documented HIV-1 RNA levels above the lower limit of quantitation of an FDA-approved assay in a sample collected in the past 90 days.
* The subject (and/or legally authorized representative, if allowed) is willing and able to provide written informed consent before providing a specimen (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an institutional review board \[IRB\]-approved waiver for parental consent for minors).

Exclusion Criteria

* A potential subject will be ineligible for the study if the subject, clinician, or medical record reports any of the following:
* Subject's HIV disease stage and/or current ART status is unknown.
* It is unknown if current or previous ART was changed or stopped due to therapy failure.
* For non-ART subjects, subject was previously on ART in the past 30 days
* Subject already participated in this study and subject's previous sample(s) was provided and not withdrawn (ie, subject has an evaluable sample in the study)
* Subject has a history of illness that the principal investigator (PI) or designee considers could interfere with or affect the conduct, results, and/or completion of the study
* Subject has a history of illness that the PI or designee considers could create an unacceptable risk to the subject if enrolled in the study

Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No